- Home
- PGHL vs MRSN Comparison
PGHL vs MRSN Comparison
Compare PGHL & MRSN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PGHL
- MRSN
- Stock Information
- Founded
- PGHL 2018
- MRSN 2001
- Country
- PGHL Hong Kong
- MRSN United States
- Employees
- PGHL N/A
- MRSN N/A
- Industry
- PGHL
- MRSN Biotechnology: Pharmaceutical Preparations
- Sector
- PGHL
- MRSN Health Care
- Exchange
- PGHL NYSE
- MRSN Nasdaq
- Market Cap
- PGHL 294.2M
- MRSN 252.0M
- IPO Year
- PGHL 2024
- MRSN 2017
- Fundamental
- Price
- PGHL $1.19
- MRSN $1.61
- Analyst Decision
- PGHL
- MRSN Buy
- Analyst Count
- PGHL 0
- MRSN 6
- Target Price
- PGHL N/A
- MRSN $6.00
- AVG Volume (30 Days)
- PGHL 7.2M
- MRSN 1.3M
- Earning Date
- PGHL 02-15-2025
- MRSN 11-13-2024
- Dividend Yield
- PGHL N/A
- MRSN N/A
- EPS Growth
- PGHL N/A
- MRSN N/A
- EPS
- PGHL 0.05
- MRSN N/A
- Revenue
- PGHL $13,464,430.00
- MRSN $34,837,000.00
- Revenue This Year
- PGHL N/A
- MRSN N/A
- Revenue Next Year
- PGHL N/A
- MRSN N/A
- P/E Ratio
- PGHL $24.54
- MRSN N/A
- Revenue Growth
- PGHL 20.83
- MRSN N/A
- 52 Week Low
- PGHL $1.03
- MRSN $1.22
- 52 Week High
- PGHL $107.36
- MRSN $6.28
- Technical
- Relative Strength Index (RSI)
- PGHL N/A
- MRSN 37.05
- Support Level
- PGHL N/A
- MRSN $2.37
- Resistance Level
- PGHL N/A
- MRSN $2.81
- Average True Range (ATR)
- PGHL 0.00
- MRSN 0.27
- MACD
- PGHL 0.00
- MRSN -0.08
- Stochastic Oscillator
- PGHL 0.00
- MRSN 11.03
About PGHL PRIMEGA GROUP HOLDINGS LIMITED
Primega Group Holdings Ltd is engaged in transportation services. It operates in the Hong Kong construction industry, mainly handling the transportation of materials excavated from construction sites. Its services principally comprise (i) soil and rock transportation services; (ii) diesel oil trading; and (iii) construction works, which mainly include ELS works and bored piling. The company provide services as a subcontractor to other construction contractors in Hong Kong. Maximum revenue is generated from soil and rock transportation services.
About MRSN Mersana Therapeutics Inc.
Mersana Therapeutics Inc is a clinical-stage biopharmaceutical company using its differentiated and proprietary ADC platforms to develop targeted drugs with increased tolerability and expanded opportunities to deliver meaningful clinical benefits to patients. The Company's early stage programs includes XMT-1660, a Dolasynthen ADC targeting B7-H4, as well as XMT-2056, a STING agonist ADC developed using the Company's Immunosynthen platform and targeting a novel epitope of human epidermal growth factor receptor 2. The Company also has two earlier stage preclinical candidates, XMT-2068 and XMT-2175, both of which leverage the Company's Immunosynthen platform and target tumor-associated antigens.